Vtv Therapeutics Inc. · NASDAQ:VTVT
Vtv Therapeutics — Investor Presentation (November 2023)
17 slides from Vtv Therapeutics's investor presentation, Nov 15, 2023
Slide 1: Improving the Lives of Millions of Patients with Type 1 Diabetes
Improving the Lives of Millions of Patients with Type 1 Diabetes NASDAQ: VTVT
Slide 2: Forward-Looking Statements
THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO T
Slide 3: New Leadership Builds upon Decades of Scientific & Clinical Expertise
New Leadership Builds upon Decades of Scientific &Clinical Expertise Paul Sekhri President & CEO Rich Nelson Head of CorpDev StevenTuch CFO Carmen Valcarce,PhD Thomas Strack,MD Chief Scientific Officer Chief Medical Officer Jon Isaacsohn,MD Chairman Martin Lafontaine Commercial Consultant 3vTv Thera
Slide 4: Distinguished SAB Continues to Support Development of Cadisegliatin (TTP399)
4vTv Therapeutics Justin Gregory, MD, MSci Asst. Professor of Pediatrics Pediatric Endocrinology Gary Koch, PhD Professor, Department of Biostatistics Director, Biometric Consulting Laboratory G. Alexander “Zan” Fleming, MD Founder & Executive Chairman, Kinexum Former FDA Supervisory Physician for D
Slide 5: Living with T1D is Like Driving Too Fast on a Dangerous Road
5vTv Therapeutics Living with T1D is Like Driving Too Fast on a Dangerous Road TOO MUCH INSULIN ~80% of patients fail to achieve adequate blood glucose control. Fear of hypoglycemia is so intense that many accept high blood glucose, risking long-term health consequences and diabetic ketoacidosis (DK
Slide 6: Hypoglycemia: The Plague of T1D
6vTv Therapeutics 1.Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169–76. 2. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T
Slide 7: Cadisegliatin is the First Liver-Selective Glucokinase Activator to Reach Phase 3
Cadisegliatin is the First Liver-Selective Glucokinase Activator to Reach Phase 3 Pancreas Effect Lowers threshold for insulin production Triggers storage of glucose as glycogen Result Rapid decline in blood sugar levels: Induces Hypoglycemia Reduces elevated blood sugar levels; Glucose released whe
Slide 8: Cadisegliatin: A First In Class Adjunctive Therapy to Insulin for the Treatment of Type 1 Diabetes
Cadisegliatin: A First In Class Adjunctive Therapy to Insulin for the Treatment of Type 1 Diabetes A Liver-Selective Glucokinase Activatorthat: 1) Reduces the Risk of Hypoglycemia 2) Improves Glycemic Control 8vTv Therapeutics
Slide 9: In Healthy Patients, the Liver Acts as a Reservoir for Glucose
In Healthy Patients, the Liver Acts as a Reservoir for Glucose Glucokinase When blood sugar is high Glucokinase, in presence of insulin, converts some glucose into glycogen for storage Insulin Glucose When blood sugar is low Glycogen reserves are broken down into glucose for release Glycogen Portal
Slide 10: With Type 1 Diabetes, Glucokinase Activity in the Liver is Impaired
With Type 1 Diabetes, Glucokinase Activity in the Liver is Impaired Glucokinase When blood sugar is high Glucokinase activity is diminished due to low insulin in the liver, reducing glycogen storage When blood sugar is low Insufficient glycogen reserves to maintain glucose homeostasis Hypoglycemia P
Slide 11: Cadisegliatin Reactivates Innate Glucose-Regulating Capacity of the Liver
Cadisegliatin Reactivates Innate Glucose-Regulating Capacity of the Liver When blood sugar is high Glucokinase is activated despite lower insulin levels When blood sugar is low Glycogen reserves available to prevent hypoglycemia Portal Vein cadisegliatin Glucokinase 11vTv Therapeutics
Slide 12: Our SimpliciT1 Trial Demonstrated Statistically & Clinically Significant Efficacy & Confirmed Safety
Our SimpliciT1 Trial Demonstrated Statistically & Clinically Significant Efficacy & Confirmed Safety Trials sponsored in part by: Randomized, Double-Blind, Placebo Controlled 2-Part Study of ~100 patients. A total of 46 patients in the treatment groups received 800mg daily of cadisegliatin. Study De
Slide 13: Cadisegliatin MoA of reducing hyperglycemic stress could be complementary to other interventions
13vTv Therapeutics Cadisegliatin MoA of reducing hyperglycemic stress could be complementary to other interventions in T1D, in addition to preventing the long-term sequelae of both hyper- and hypoglycemia
Slide 14: High Level Commercial Opportunity Assessment
1 Type 1 Diabetes Index website. Available at 1dindex.org. Accessed on September 28th, 2023. 2 Prescription Drug Disclosure program. Texas HHS. Available at https://www.dshs.texas.gov/prescription-drug-price-disclosure-program 3 Internal, vTv Therapeutics High Level Commercial Opportunity Assessment
Slide 15: Pipeline Creates Additional Upside
Pipeline Creates Additional Upside vTv Partner vTv + Partner 15vTv Therapeutics
Slide 16: We Have the Opportunity to Ease the Burden of Managing T1D
We Have the Opportunity to Ease the Burden of Managing T1D and Improve the Lives of Patients Living with Type 1 Diabetes 16vTv Therapeutics
Slide 17: Conclusions
17vTv Therapeutics Cadisegliatin significantly improved glycemic control Cadisegliatin had a favorable safety profile: reduction of hypoglycemia and ketosis events FDA has granted cadisegliatin Breakthrough Designation for the Treatment of T1D Poised to initiate phase 3 trials for cadisegliatin Conc
vTv Therapeutics — Investor Presentation (November 2023) on 6ix